AMRX

Amneal Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

8.090

-0.08(-0.979%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

8.215

Open

8.170

VWAP

Vol

1.54M

Mkt Cap

2.54B

Low

8.070

Amount

EV/EBITDA(TTM)

8.72

Total Shares

308.65M

5.08B

EV/OCF(TTM)

16.57

P/S(TTM)

0.90

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

744.56M

+6.1%

0.175

+9.31%

779.66M

+10.99%

0.175

+9.25%

791.74M

+8.38%

0.154

+28.2%

Estimates Revision

The market is revising Downward the revenue expectations for Amneal Pharmaceuticals, Inc. (AMRX) for FY2025, with the revenue forecasts being adjusted by -0.35% over the past three months. During the same period, the stock price has changed by 5.61%.

Revenue Estimates for FY2025

Revise Downward

-0.35%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.95%

In Past 3 Month

Stock Price

Go Up

+5.61%

In Past 3 Month

3 Analyst Rating

42.15% Upside

Wall Street analysts forecast AMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is 11.50 USD with a low forecast of 11.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

42.15% Upside

Current: 8.090

Low

11.00

Averages

11.50

High

12.00

42.15% Upside

Current: 8.090

Low

11.00

Averages

11.50

High

12.00

Goldman Sachs

Matt Dellatorre

Buy

initiated

$12

2025-06-06

Reason

Goldman Sachs

Matt Dellatorre

Price Target

$12

2025-06-06

initiated

Buy

Reason

Goldman Sachs analyst Matt Dellatorre initiated coverage of Amneal Pharmaceuticals with a Buy rating and $12 price target. The firm expects continued momentum across the portfolio and sees upside to consensus estimates. Goldman sees Amneal's generics segment remaining the key component and driver of EBITDA growth, driven by the company's strong product pipeline, including biosimilar and sterile injectable launches.

Barclays

Balaji Prasad

Buy

Maintains

$10 → $11

2025-03-03

Reason

Barclays

Balaji Prasad

Price Target

$10 → $11

2025-03-03

Maintains

Buy

Reason

JP Morgan

Chris Schott

Hold

Buy

Upgrades

$9 → $12

2025-02-24

Reason

JP Morgan

Chris Schott

Price Target

$9 → $12

2025-02-24

Upgrades

Hold

Buy

Reason

Piper Sandler

David Amsellem

Buy

Maintains

$9 → $11

2024-11-11

Reason

Piper Sandler

David Amsellem

Price Target

$9 → $11

2024-11-11

Maintains

Buy

Reason

Piper Sandler raised the firm's price target on Amneal Pharmaceuticals to $11 from $9 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 16c on revenue of $702M, compared to Street estimates of 13c and $694M, respectively. The company reiterated 2024 total revenue and adjusted EBITDA guidance ranges of $2.7B-$2.8B and $610M-$630M, respectively.

Truist Securities

Les Sulewski

Strong Buy

Maintains

$10 → $12

2024-10-02

Reason

Truist Securities

Les Sulewski

Price Target

$10 → $12

2024-10-02

Maintains

Strong Buy

Reason

Truist analyst Les Sulewski raised the firm's price target on Amneal Pharmaceuticals to $12 from $10 and keeps a Buy rating on the shares. The firm has followed up with the company's management post Metsera collaboration news to gain insight into the agreement and entrance into the GLP1 space as a supplier for U.S./E.U. markets and commercial leadership ex-U.S., the analyst tells investors in a research note. Despite Metsera's early stage foray into next-gen GLP1s, the partnership solidifies Amneal as a commercial partner with scale, opening the door for additional GLP1 manufacturing contracts, the firm states, adding that its $200M investment in a new India facility will leverage Amneal's complex manufacturing knowhow and boost its peptide footprint to drive additional partnerships.

JP Morgan

Chris Schott

Sell

Hold

Upgrades

2024-09-06

Reason

JP Morgan

Chris Schott

Price Target

2024-09-06

Upgrades

Sell

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amneal Pharmaceuticals Inc (AMRX.N) is 12.13, compared to its 5-year average forward P/E of 7.45. For a more detailed relative valuation and DCF analysis to assess Amneal Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Overvalued

5Y Average PE

7.45

Current PE

12.13

Overvalued PE

10.55

Undervalued PE

4.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

6.73

Current EV/EBITDA

7.65

Overvalued EV/EBITDA

7.69

Undervalued EV/EBITDA

5.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

0.44

Current PS

0.83

Overvalued PS

0.71

Undervalued PS

0.17

Financials

Annual

Quarterly

FY2025Q1

YoY :

+5.50%

695.42M

Total Revenue

FY2025Q1

YoY :

+12.46%

95.80M

Operating Profit

FY2025Q1

YoY :

-130.14%

24.62M

Net Income after Tax

FY2025Q1

YoY :

-113.33%

0.04

EPS - Diluted

FY2025Q1

YoY :

-54.84%

-10.91M

Free Cash Flow

FY2025Q1

YoY :

+1.91%

36.80

Gross Profit Margin - %

FY2025Q1

YoY :

+65.66%

8.25

FCF Margin - %

FY2025Q1

YoY :

-128.57%

3.54

Net Margin - %

FY2025Q1

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

2.0M

USD

3-6

Months

46.6M

USD

6-9

Months

1.9M

USD

0-12

Months

491.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

14.2K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

2.0M

USD

3-6

Months

46.6M

USD

6-9

Months

1.9M

USD

0-12

Months

491.4K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AMRX News & Events

Events Timeline

2025-07-21 (ET)

2025-07-21

07:42:11

Amneal Pharmaceuticals announces proposed refinancing of credit agreement

2025-07-21

07:40:51

Amneal Pharmaceuticals sees Q2 revenue $720M-$730M, consensus $753.34M

2025-07-18 (ET)

2025-07-18

07:03:49

Knight Therapeutics announces CREXONT NDS accepted for Health Canada review

News

3.0

07-29NASDAQ.COM

Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why

8.5

07-21Newsfilter

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

9.5

07-21Newsfilter

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

People Also Watch

Recursion Pharmaceuticals Inc

Renew Energy Global PLC

Albany International Corp

Kulicke and Soffa Industries Inc

Companhia Paranaense de Energia

Brookfield Wealth Solutions Ltd

67.710

USD

+0.31%

Urban Edge Properties

Energizer Holdings Inc

23.470

USD

-0.93%

FAQ

What is Amneal Pharmaceuticals Inc (AMRX) stock price today?

The current price of AMRX is 8.09 USD — it has decreased -0.98 % in the last trading day.

AMRX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

AMRX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Amneal Pharmaceuticals Inc (AMRX) stock price today?

What is Amneal Pharmaceuticals Inc (AMRX)'s business?

What is the price predicton of AMRX Stock?

What is Amneal Pharmaceuticals Inc (AMRX)'s revenue for the last quarter?

What is Amneal Pharmaceuticals Inc (AMRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Amneal Pharmaceuticals Inc (AMRX)'s fundamentals?

How many employees does Amneal Pharmaceuticals Inc (AMRX). have?

What is Amneal Pharmaceuticals Inc (AMRX) market cap?